Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane

Journal of Endocrinological Investigation

Volumn 29, Issue 6, 2006, Pages 560-562

  Sperone, Paola ^a   Berruti, A ^a   Gorzegno, G ^a   Paccotti, P ^b   Terzolo, M ^b   Porpiglia, F ^a   Angeli, A ^b   Dogliotti, L ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Advanced adreno cortical carcinoma; Chemotherapy; Mitotane

Indexed keywords

ANDROGEN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; HYDROCORTISONE; MITOTANE;

ABDOMEN; ADRENAL CORTEX CARCINOMA; ADRENAL GLAND; ADRENAL INSUFFICIENCY; ADRENALECTOMY; ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LONG TERM CARE; MAINTENANCE THERAPY; METASTASIS; NAUSEA AND VOMITING; THORAX; TUMOR NECROSIS;

EID: 33746662841     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03344148     Document Type: Article

References (13)

1. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian Registry for adrenal cortical carcinoma: analysis of a multiistitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996, 119: 161-70.
2. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surgery 2001, 25: 891-7.
3. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004, 60: 273-87.
4. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990, 322: 1195-201.
5. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenal cortical carcinoma: a Southwest Oncology Group Study. Cancer 2000, 88: 1159-65.
6. Bonacci R, Gigliotti A, Baudin E, et al. Cytotoxic therapy with etoposide and cisplatin in advanced adreno-cortical carcinoma. Br J Cancer 1998, 78: 546-9.
7. Schlumberger M, Brugieres L, Gicquel C, Travagli JP, Droz JP, Parmentier C. 5-fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991, 67: 2997-3000.
8. Van Slooten H, van Oosterom AT. CAP (cyclophosphamide, doxorubicin and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983, 67: 377-9.
9. Bukowski RM, Wolfe M, Levine HS. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma. A Southwest Oncology Group Study. J Clin Oncol 1993, 11: 161-5.
10. Villa R, Orlandi L, Berruti A, Dogliotti L, Zaffaroni N. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int J Oncol 1999, 14: 133-8.
11. Bates S, Shieh CY, Mickley LA, et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/ P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 1991, 73: 18-29.
12. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide doxorubicin and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer 1998, 83: 2194-200.
13. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Related Cancer 2005, 12: 657-66.